A large number of studies have shown that TP53 mutation was not only a poor prognostic factor for NSCLC but also increases the resistance of patients with EGFR mutation to EGFR-TKI therapy [24–26]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.